Clinical Trials Logo
  1. Home
  2. Rhinoconjunctivitis
  3. NCT00818181
  4. Details
NCT00818181 Clinical Trial

Open Label Safety Study of a Birch Pollen Allergen Extract

Rhinoconjunctivitis Clinical Trial

Official title:
A Multicentre Open Label Safety Study of a Sublingual Specific Immunotherapy With a Solution of Birch Pollen Allergen Extract in Patients With Clinically Relevant Birch Pollen Allergy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00818181
Other study ID # AL0206st
Secondary ID 2007-006053-24
Status Completed
Phase Phase 2
First received January 6, 2009
Last updated March 8, 2013
Start date June 2008
Est. completion date August 2010

Study information
Verified date March 2013
Source Allergopharma GmbH & Co. KG
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

This trial is performed to assess safety of a sublingual birch pollen extract.

Recruitment information / eligibility
Status Completed
Enrollment 73
Est. completion date August 2010
Est. primary completion date February 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Allergic rhinoconjunctivitis attributable to birch pollen

- Positive SPT

- Positive EAST

Exclusion Criteria:

- Serious chronic diseases

- Other perennial allergies

- Partly controlled asthma

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Biological: AL0206st

Locations
Country Name City State
Germany Prof. Dr. Nicolas Hunzelmann Cologne

Sponsors (1)
Lead Sponsor Collaborator
Allergopharma GmbH & Co. KG

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Other Immunologic parameters Immunologic parameters (IgE, IgG1 and IgG4) were evaluated during the course of the study in order to obtain evidence of the immunologic effects. during the course of the study No
Primary number of patients with at least one adverse event Between Visit 03 and Visit 05 (June 2008 - January 2009) 8 months Yes
Secondary Systemic reactions The occurrence of systemic reactions during the entire treatment period: For this purpose patients completed a diary covering the treatment phase. Entire treatment period Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05560698 - A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment N/A
Completed NCT02849210 - A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea Phase 1
Completed NCT02150343 - Phase II HDM-SPIRE Safety and Efficacy Study Phase 2
Completed NCT02340130 - Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma Phase 2
Completed NCT01949428 - House Dust Mite Observational Study N/A
Completed NCT01923792 - ToleroMune House Dust Mite Follow on Study N/A
Completed NCT01949415 - An Optional Investigation of Biomarkers of Efficacy N/A
Completed NCT01949441 - ToleroMune House Dust Mite (HDM) Tolerability Study Phase 2
Completed NCT01447784 - ToleroMune House Dust Mites (HDM) Exposure Chamber Study Phase 2
Recruiting NCT04435990 - Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites Phase 3
Active, not recruiting NCT05960266 - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study Early Phase 1
Completed NCT01620762 - Phase III Cat-PAD Study Phase 3
Completed NCT01720251 - Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy Phase 2
Completed NCT01448603 - ToleroMune Ragweed Follow up Study N/A
Completed NCT01353755 - 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma Phase 3
Completed NCT00574210 - PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm) Phase 2
Completed NCT00537342 - Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT) Phase 3
Completed NCT00540631 - Multicenter Trial of Immunotherapy With House Dust Mite Allergoid Phase 3
Completed NCT05540717 - Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen Phase 3
Completed NCT02844842 - Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice

External Links